跳至主要内容
临床试验/EUCTR2017-001253-13-BE
EUCTR2017-001253-13-BE进行中(未招募)1 期

Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? - ROCHIMS (Role of Cerebral Hypoperfusion In Multiple Sclerosis)

Z Brussel0 个研究点目标入组 30 人开始时间: 2017年7月11日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Patients with the diagnosis of relapsing-remitting MS, according to the 2010 Revised Mc Donald Criteria
  • - Age > 18 years
  • - Written informed consent must be obtained
  • - EDSS score < or equal to 4
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • - Clinical evidence of MS relapse within 3 months prior to inclusion.
  • - Known contra-indications for bosentan: liver dysfunction (AST and/or ALT > 3 x ULN), use of cyclosporine A and glibenclamide, allergy
  • - Pregnancy

研究者

发起方
Z Brussel

相似试验